Mechanisms of Immune Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-20

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. The purpose of this study is to learn more about the changes in genes, cells and proteins that cause immune deficiency diseases.
2. The early stages of the study will focus on two groups of patients:

1. members of families in which several persons have symptoms or medical histories that suggest immune deficiency.
2. Patients who have received treatments with medications or drugs that affect functions of the immune system (secondary immune deficiencies).

It is hoped that studies will provide guidelines for extension of the research to other patient groups. Up to 200 patients and family members will be invited to participate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

NCT03409796

Celiac Disease

COMPLETED NA

Allergy and Immunology Natural History Study

NCT05584488

Immune Deficiency Immune Dysregulation Disorder Allergic Inflammation

RECRUITING

Pathophysiology of Inborn Immunodeficiencies

NCT03422614

Primary Immune Deficiency Disorder

UNKNOWN

Study in Allergic Adults to Support the Development of Immunological Assays

NCT01320137

Immunologic Tests

COMPLETED NA

Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders

NCT06773546

Inborn Errors of Immunity

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The experiments that are proposed in this portion of the study are intended to:

1. characterize the significance of the variant form of EZH2 identified in this family. They will characterize the degree of methylation of lysine 27 of histone H3 in subjects with the variant and members of the same family who have the wild type gene. The functional methyltransferase activity of the variant and wild type genes will be measured.
2. characterize the current status of B-cell maturation and function in subjects with either the variant gene and the wild type gene.
3. characterize B-cell function (antibody production) and the quality of antibody produced after immunizations in subjects with the wild type gene or the variant gene.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Individuals with immune deficiencies

aged 18 years or older and have an immune deficiency

No interventions assigned to this group

Family members

aged 18 years or older and are related to a person who has an immune deficiency

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Immunodeficiency disease; or
2. family member of individual with immunodeficiency disease

Exclusion Criteria

1. Persons with immune deficiencies that are secondary to other diseases such as malignancies.
2. Persons who do not have immune deficiencies, persons who are not meet eligibility criteria

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No